autologous bacterial vaccine

The autologous bacterial vaccine is a personalized immunotherapeutic agent developed by the Instituto de Investigación Marqués de Valdecilla (IDIVAL) for the treatment of chronic infections, specifically prosthetic joint infections (PJI). The vaccine is manufactured by isolating the specific bacterial strain(s) responsible for a patient's infection, culturing them, and then inactivating them (typically through heat or chemical means). When administered to the patient, the vaccine is intended to stimulate a targeted immune response against the pathogen, helping to overcome the protective environment of bacterial biofilms that often render conventional antibiotics ineffective. This approach is particularly relevant for patients with recalcitrant PJI where surgical options are limited or have failed.

Other names

autovaccinepersonalized bacterial vaccine